As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Scientific and medical experts are increasingly recognising obesity as a serious chronic disease.

As leaders in the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. We aim to be the leading force in the science behind obesity. Learn more about our ambitious R&D pipeline.

6 days ago · Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion ...

We are on a mission to increase awareness about obesity and its causes, destigmatise this chronic disease, and provide diverse treatment options. We are working towards a future where we can help prevent and treat obesity – and even ultimately cure it.

Here you will find everything related to our obesity treatments, information on how to use your medication devices, as well as information about our clinical trials, and our treatment innovations. Explore our obesity page.

At Novo Nordisk, we are dedicated to making obesity a healthcare priority. We are committed to helping improve the lives of people with obesity by changing how the world sees, prevents and treats obesity.

Jan 27, 2025 · Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the...

Novo Nordisk® is committed to discovering, developing, and delivering resources and tools to help enhance weight-loss discussion and motivate healthy changes.

Feb 3, 2025 · Novo Nordisk plans further clinical development of amycretin for obesity and overweight treatment. The phase 1b/2a results show the potential of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist.

6 days ago · With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024’s fourth quarter, the Danish drugmaker feels confident that it can maintain its edge over chief rival Eli ...